Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

Onconova Therapeutics Inc. (NASDAQ: ONTX) was absolutely crushed to start out the week after the company reported results from its late-stage cancer study.

Is Onconova Therapeutics in Serious Trouble After This Late-Stage Cancer Study?

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS)

Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2020 Results - Earnings Call Transcript

Shares of Onconova Therapeutics (NASDAQ:ONTX) decreased 1.89% in after-market trading after the company reported Q2 results.

Onconova Therapeutics: Q2 Earnings Insights

Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET

Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12

Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020

NEWTOWN, Pa., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that on August 3, 2020 it received a letter from The Nasdaq Stock Market LLC stating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock had a minimum closing price of at least $1.00 per share for a minimum ten consecutive business days.

Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.

Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?

Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020 Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020

Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

NEWTOWN, Pa., July  23, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the publication (Molecular Cell 79, 180-190, 2020) of in vitro data further supporting rigosertib’s role in modulating RAS cellular signaling.

Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy

RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies

Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS

Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.

Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

NEWTOWN, Pa., June  23, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced its participation in the Noble Capital Markets c-suite webinar series.

Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar

NEWTOWN, Pa., June  22, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS) today announced an investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) lung adenocarcinoma has begun enrolling patients.

Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

RAS Pathway Mutations Were Observed More Commonly in Patients That Progressed on HMA Therapy vs Patients That Failed HMA Therapy Completely RAS Pathway Mutations Were Observed More Commonly in Patients That Progressed on HMA Therapy vs Patients That Failed HMA Therapy Completely

Onconova Therapeutics Announces Presentation  at the 25th Congress of the  European Hematology Association (EHA)

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q1 2020 Results - Earnings Call Transcript

Conference Call and Webcast Scheduled Today, May 14 at 4:30 p.m. ET Conference Call and Webcast Scheduled Today, May 14 at 4:30 p.m. ET

Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

NEWTOWN, Pa., May  11, 2020  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that, as disclosed in the Company’s Definitive Proxy Statement for the Company’s 2020 Annual Meeting of Stockholders, due to the public health impact of the COVID-19 pandemic, the Company’s Annual Meeting of Stockholders will be held in a virtual meeting webcast format, beginning at 10:30 a.m. EDT on Wednesday, May 27, 2020. Stockholders will not be able to attend the Annual Meeting in person.

Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q4 2019 Results - Earnings Call Transcript

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Tuesday, March 24, 2020 Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Tuesday, March 24, 2020

Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results

As of late, it has definitely been a great time to be an investor in Onconova Therapeutics.

Will Onconova Therapeutics Continue to Surge Higher?

Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.

Onconova (ONTX) to Report Q4 Earnings: What's in Store?

Onconova: The Ingredients For Success Are Finally Here

As of late, it has definitely been a great time to be an investor of Onconova Therapeutics, Inc. (ONTX).

News for Onconova Therapeutics Stock (ONTX)